Genfit SA (GNFT) Price & Analysis

Compare

266 Followers

GNFT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.55 - $6.42

Previous CloseN/A

Volume1.39K

Average Volume (3M)3.65K

Market Cap

$204.69M

Enterprise Value$164.61M

Total Cash (Recent Filing)$61.65M

Total Debt (Recent Filing)$67.80M

Price to Earnings (P/E)123.9

Beta0.63

Next Earnings

Sep 22, 2025

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.64

Shares Outstanding50,002,834

10 Day Avg. Volume3,289

30 Day Avg. Volume3,649

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.80

Enterprise Value/Revenue2.11

Enterprise Value/Gross Profit2.13

Enterprise Value/Ebitda6.68

Forecast

1Y Price Target

$9.00

Price Target Upside117.39% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical TrialsPreliminary safety data from a study with GNS561 and trametinib in patients with KRAS-mutated cholangiocarcinoma supported the study's continuation, reflecting positive developments in their clinical trials.

Financial StabilityGENFIT entered into a royalty financing agreement with HealthCare Royalty (HCRx) for up to €185M in total funding, providing financial stability and resources for future projects.

Pipeline DevelopmentMultiple clinical catalysts later in 2025 could boost confidence in the rare liver disease pipeline.

Research And DevelopmentGENFIT announced a list of its 2025 milestones that includes up to four clinical data readouts from its Acute on-Chronic Liver Failure (ACLF) programs, indicating progress in their research and development efforts.

Bears Say

Debt ManagementPlans to eliminate outstanding convertible debt should provide further capital flexibility for the company moving forward.

Patient EnrollmentA protocol amendment to improve the logistics of enrolling ACLF patients has been implemented to accelerate patient enrollment, indicating proactive steps to enhance clinical trial efficiency.

Genfit SA News

Genfit assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Genfit (GNFT) with a Buy rating and $9 price target The company is...

9d ago

GNFT

Genfit SA: Strategic Positioning and Undervalued Potential in Biotechnology Sector

Genfit SA (GNFT) has received a new Buy rating, initiated by H.C. Wainwright analyst, Brandon Folkes. Brandon Folkes...

9d ago

GNFT

Genfit SA’s New Study on G1090N: A Potential Game-Changer?

Genfit SA (($GNFTF)), Genfit (($GNFT)) announced an update on their ongoing clinical study. Genfit SA (GNFTF) has announced...

21d ago

GNFT

GENFIT Releases Half-Year Liquidity Contract Report

Genfit SA ( ($GNFT) ) has shared an announcement. On July 8, 2025, GENFIT announced the half-year report...

2M ago

GNFT

GENFIT Shareholders Approve Key Resolutions at June 2025 Meeting

The latest announcement is out from Genfit SA ( ($GNFT) ). On June 17, 2025, GENFIT announced the...

2M ago

GNFT

GENFIT Reports Strong Q1 Financials and Leadership Change

Genfit SA ( ($GNFT) ) has shared an announcement. On May 22, 2025, GENFIT reported its financial results...

3M ago

GNFT

GENFIT Secures €26.5 Million Milestone with Ipsen’s Iqirvo® Approval in Italy

Genfit SA ( ($GNFT) ) has shared an update. On May 20, 2025, GENFIT announced it will receive...

3M ago

GNFT

Genfit to receive EUR 26.5M Iqirvo milestone payment from Ipsen agreement

Genfit (GNFT) announced that Ipsen’s Iqirvo has been granted pricing and reimbursement in Italy for Primary Biliary Cholangitis....

3M ago

GNFT

GENFIT Publishes 2025 Extra-Financial Performance Report

The latest update is out from Genfit SA ( ($GNFT) ). On May 14, 2025, GENFIT announced the...

4M ago

GNFT

GENFIT Announces Details for June 2025 Shareholders’ Meeting

Genfit SA ( ($GNFT) ) has shared an announcement. On May 7, 2025, GENFIT announced the details of...

4M ago

GNFT

GENFIT Highlights ACLF Research at EASL Congress 2025

Genfit SA ( ($GNFT) ) just unveiled an announcement. On May 5, 2025, GENFIT announced its participation in...

4M ago

GNFT

GENFIT Releases 2024 Annual Reports, Enhancing Transparency

Genfit SA ( ($GNFT) ) just unveiled an announcement. On April 29, 2025, GENFIT announced the publication of...

4M ago

GNFT

Genfit announces final terms for dual proposal to 2025 Oceanes holders

Genfit (GNFT) announced the final terms of the 2025 Oceanes repurchase proposal and the consent fee that would...

7M ago

GNFT

Genfit announces positive CHMP opinion for Ipsen’s Iqirvo

GENFIT (GNFT) announced the positive opinion issued by the Committee for Medicinal Products for Human Use of the...

1y ago

GNFT

GNFT FAQ

What was Genfit SA’s price range in the past 12 months?

Genfit SA lowest stock price was $2.55 and its highest was $6.42 in the past 12 months.

What is Genfit SA’s market cap?

Genfit SA’s market cap is $204.69M.

When is Genfit SA’s upcoming earnings report date?

Genfit SA’s upcoming earnings report date is Sep 22, 2025 which is in 25 days.

How were Genfit SA’s earnings last quarter?

Genfit SA released its earnings results on Apr 24, 2025. The company reported -$0.637 earnings per share for the quarter, missing the consensus estimate of -$0.256 by -$0.381.

Is Genfit SA overvalued?

According to Wall Street analysts Genfit SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Genfit SA pay dividends?

Genfit SA does not currently pay dividends.

What is Genfit SA’s EPS estimate?

Genfit SA’s EPS estimate is -0.15.

How many shares outstanding does Genfit SA have?

Genfit SA has 50,002,834 shares outstanding.

What happened to Genfit SA’s price movement after its last earnings report?

Genfit SA reported an EPS of -$0.637 in its last earnings report, missing expectations of -$0.256. Following the earnings report the stock price went down -0.817%.

Which hedge fund is a major shareholder of Genfit SA?

Currently, no hedge funds are holding shares in GNFT

Genfit SA Stock Smart Score

Underperform

Fundamentals

Return on Equity

2.17%

Trailing 12-Months

Asset Growth

-18.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Genfit SA

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Genfit SA (GNFT) Earnings & Revenues

Historic Earnings Reports

GNFT Stock 12 Month Forecast

Average Price Target

$9.00

▲(117.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","4":"$4","6":"$6","8":"$8","10":"$10"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4,6,8,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.8,4.2,4.6,5,5.4,5.8,6.2,6.6,7,7.4,7.8,8.2,8.600000000000001,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.8,4.2,4.6,5,5.4,5.8,6.2,6.6,7,7.4,7.8,8.2,8.600000000000001,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.8,4.2,4.6,5,5.4,5.8,6.2,6.6,7,7.4,7.8,8.2,8.600000000000001,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.56,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.18,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.34,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.73,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >